Cellectis (NASDAQ:CLLS) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLSFree Report) in a research report released on Monday. The brokerage issued a sell rating on the biotechnology company’s stock.

CLLS has been the topic of a number of other reports. Oppenheimer decreased their target price on Cellectis from $11.00 to $10.00 and set an outperform rating on the stock in a research report on Wednesday, June 12th. JMP Securities reiterated a market outperform rating and set a $6.00 target price on shares of Cellectis in a research report on Friday, May 31st.

Read Our Latest Report on CLLS

Cellectis Trading Up 1.8 %

Shares of CLLS stock opened at $1.95 on Monday. The business’s fifty day moving average price is $2.52 and its 200 day moving average price is $2.68. Cellectis has a 1-year low of $0.96 and a 1-year high of $3.77. The firm has a market capitalization of $108.38 million, a PE ratio of -1.51 and a beta of 3.10. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.63 and a quick ratio of 1.63.

Cellectis (NASDAQ:CLLSGet Free Report) last announced its quarterly earnings data on Tuesday, May 28th. The biotechnology company reported ($0.15) earnings per share for the quarter. Cellectis had a negative return on equity of 67.41% and a negative net margin of 529.81%. The business had revenue of $6.50 million for the quarter. As a group, sell-side analysts forecast that Cellectis will post -0.54 EPS for the current fiscal year.

Institutional Trading of Cellectis

An institutional investor recently raised its position in Cellectis stock. Principal Financial Group Inc. grew its stake in Cellectis S.A. (NASDAQ:CLLSFree Report) by 6.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 424,533 shares of the biotechnology company’s stock after acquiring an additional 24,906 shares during the quarter. Principal Financial Group Inc. owned about 0.76% of Cellectis worth $1,125,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

(Get Free Report)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

Featured Stories

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.